Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524731 | NSE Symbol : | ISIN : INE354A01013 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
12-May-2025	20-May-2025	Accounts	Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve the audited financial results for the quarter and financial year ended on 31st March 2025 and recommend dividend if any. Outcome of Board Meeting Held on 20th May, 2025. (As Per BSE Announcement Dated on: 19/05/2025)
20-Jan-2025	28-Jan-2025	Quarterly Results	Quarterly Results JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve unaudited financial results for the quarter and nine months ended on 31st December, 2024. (As Per BSE Announcement Dated on 20/01/2025) Outcome of the Board Meeting held today on 28th January, 2025, inter-alia to approved standalone unaudited financial results for the quarter and nine months ended on 31st December,2024. (As Per BSE Announcement Dated on: 28/01/2025)
28-Oct-2024	05-Nov-2024	Quarterly Results	Quarterly Results JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 ,inter alia, to consider and approve Standalone unaudited financial results for the quarter and half year ended on 30th September, 2024. Read less.. (As Per BSE Announcement Dated on 28.10.2024) standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2024. Outcome of Board Meeting held today on 05-11-2024, inter-alia to approved Standalone Unaudited Financial Results For The Quarter and half year Ended On 30Th September, 2024. (As per BSE Announcement Dated on 05/11/2024)
18-Jul-2024	26-Jul-2024	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the standalone unaudited financial results of the Company for the quarter ended on 30th June 2024. Standalone unaudited Financial Results for the quarter ended on 30th June 2024. (As Per BSE Announcement dated on 26.07.2024)
18-May-2024	28-May-2024	Accounts	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve Audited Financial Results for the Quarter and Financial Year ended on 31.03.2024 and to consider recommendation of dividend if any. Outcome of Board Meeting Held on 28th May, 2024 Intimation of Change in Directors on the Board of the Company (As Per BSE Announcement dated on 28.05.2024)
12-Apr-2024	12-Apr-2024	Others	Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we hereby inform you about the Changes in Senior Management personnel of the Company.
19-Jan-2024	06-Feb-2024	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve the Standalone unaudited financial results for the quarter and nine months ended on 31st December 2023. Outcome of Board Meeting held today, i.e. 06th February, 2024 -Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2023. (As Per BSE Announcement Dated on: 06/02/2024)
27-Oct-2023	07-Nov-2023	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve unaudited financial results for the quarter and half year ended on 30th September 2023. Outcome of Board Meeting held today, i.e. 07th November, 2023 - Unaudited Financial Results for the quarter and half year ended on 30th September, 2023. The Directors at their meeting held on 7th November, 2023 have declared standalone unaudited financial results for the quarter and half year ended on 30.09.2023 (As Per BSE Announcement Dated on 07/11/2023)
25-Jul-2023	08-Aug-2023	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve standalone unaudited financial results of the Company for the quarter ended on 30th June 2023. Outcome of Board Meeting held today, i.e. 8th August, 2023- Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2023. (As Per BSE Announcement dated on 08.08.2023)
12-May-2023	23-May-2023	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve Audited Financial Statements for the Financial Year 2022-23 to declare dividend if any. The Board of Directors at their meeting held on 23rd May, 2023 recommended a dividend of Rs.14.40 per equity share of Rs.10/- each. (As per BSE Announcement Dated on 23/05/2023)
27-Jan-2023	07-Feb-2023	Quarterly Results	Quarterly Results JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 ,inter alia, to consider and approve the unaudited financial results for the quarter and nine months ended on 31st December, 2022. (As Per BSE Announcement dated on 27.01.2023) Results-Financial Results for the quarter and nine months ended on 31st December, 2022. (As Per BSE Announcement Dated on 07/02/2023) Intimation of timings of Board Meeting held on 07th February, 2023 (As Per BSE Announcement dated on 08.02.2023)
28-Nov-2022	01-Dec-2022	Buy Back	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/12/2022 inter alia to consider and approve buy-back of shares. Outcome of Board Meeting held today inter alia to approve buy back of shares of the Company through open market route through stock exchange mechanism. Revised outcome -clarification The Board of Directors at their meeting held today approved Buy-back of shares. Appointment of Cost Auditors (As per BSE Announcement Dated on 01/12/2022) Extract of minutes of the meeting of the board of the Co. held on 1st December, 2022 inter alia to approve buy-back of shares of the Company Board Resolution pursuant to the provisions of the SEBI (Buy-back of Securities) Regulations, 2018. (As per BSE Announcement Dated on 05/12/2022)
29-Oct-2022	08-Nov-2022	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 inter alia to consider and approve the unaudited financial results for the quarter and half year ended on 30th September 2022. Standalone Unaudited Financial Results for the Quarter and half year ended on 30th September, 2022. (As Per BSE Announcement Dated on 08.11.2022) Revised outcome of the Board Meeting Held On 08th November, 2022 to approved Standalone Unaudited Financial Results for the Quarter and half year ended on 30th September, 2022. (As Per BSE Announcement Dated on 09/11/2022)
21-Jul-2022	01-Aug-2022	Quarterly Results	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2022 inter alia to consider and approve the Unaudited Standalone Financial Results for the quarter ended on 30th June 2022. Un-audited Quarterly financial result for the quarter from 1st April to 30th June, 2022 (As Per BSE Announcement Dated on 01.08.2022)
16-May-2022	27-May-2022	Accounts	JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve audited standalone financial results for the quarter and financial year ended on 31.03.2022 and to consider the recommendation of dividend if any. Outcome of Board Meeting held on 27th May, 2022 The board approved audited financial results for the financial year 2021-22. The board also recommended dividend @ Rs 12/- (120%) per Rs. 10/- paid 4589378 equity shares of the Company The Board of directors at their meeting held on 27th May, 2022 recommended a dividend of Rs.12/- (120%) per Rs.10/- paid-up 4589378 equity shares of the Company. Outcome of Board Meeting held on 27th May, 2022 The board of directors at their meeting held on 27th May2022, declared book closure and record date in connection with the 37th AGM to be held on 27th May, 2022. (As Per BSE Announcement Dated on 27.05.2022) Newspapers Publications of Audited Financial Results for the quarter and financial year ended on 31° March, 2022. (As Per BSE Announcement Dated on 28.05.2022)

1 2

LOGIN HERE

Jenburkt Pharmaceuticals Ltd

Board Meeting